November 2024 Publications
- Bioinformatics Analysis and Immunogenicity Assessment of the Novel Multi-Stage DNA Vaccine W541 Against Mycobacterium Tuberculosis. Yang Y, Xue Y, Wang X, Wang L, Wang J, Zhang J, Liu Y, Liang Y, Wu X. Immun Inflamm Dis. 2024 Nov;12(11):e70074. doi: 10.1002/iid3.70074.
- Multilevel Proteomics Reveals Epigenetic Signatures in BCG-Mediated Macrophage Activation. Schaefer Z, Iradukunda J, Lumngwena EN, Basso KB, Blackburn JM, Parker IK. Mol Cell Proteomics. 2024 Nov;23(11):100851. doi: 10.1016/j.mcpro.2024.100851. Epub 2024 Oct 2.
- Single-cell sequencing: Current applications in various tuberculosis specimen types. Zeng Y, Ma Q, Chen J, Kong X, Chen Z, Liu H, Liu L, Qian Y, Wang X, Lu S. Cell Prolif. 2024 Nov;57(11):e13698. doi: 10.1111/cpr.13698. Epub 2024 Jul 2.
- Intravenous Bacillus Calmette-Guérin (BCG) Induces a More Potent Airway and Lung Immune Response than Intradermal BCG in Simian Immunodeficiency Virus-infected Macaques. Jauro S, Larson EC, Gleim JL, Wahlberg BM, Rodgers MA, Chehab JC, Lopez-Velazques AE, Ameel CL, Tomko JA, Sakal JL, DeMarco T, Borish HJ, Maiello P, Potter EL, Roederer M, Ling Lin P, Flynn JL, Scanga CA. J Immunol. 2024 Nov 1;213(9):1358-1370. doi: 10.4049/jimmunol.2400417.
- Identifying WHO global priority endemic pathogens for vaccine research and development (R&D) using multi-criteria decision analysis (MCDA): an objective of the Immunization Agenda 2030. Hasso-Agopsowicz M, Hwang A, Hollm-Delgado MG, Umbelino-Walker I, Karron RA, Rao R, Asante KP, Sheel M, Sparrow E, Giersing B. EBioMedicine. 2024 Nov 4:105424. doi: 10.1016/j.ebiom.2024.105424. Epub ahead of print.
- Mycobacterium tuberculosis VII secretion system effector molecule Rv2347c blocks the maturation of phagosomes and activates the STING/TBK1 signaling pathway to inhibit cell autophagy. Jiang Z, Zhen J, Abulikena Y, Gao C, Huang L, Huang T, Xie J. Microbiol Spectr. 2024 Nov 5;12(11):e0118824. doi: 10.1128/spectrum.01188-24. Epub 2024 Sep 23.
- Intranasal vaccination with engineered BCG expressing CCL2 induces a stronger immune barrier against Mycobacterium tuberculosis than BCG. Guo S, Ouyang J, Hu Z, Cao T, Huang C, Mou J, Gu X, Liu J. Mol Ther. 2024 Nov 6;32(11):3990-4005. doi: 10.1016/j.ymthe.2024.09.021. Epub 2024 Sep 18.
- IFNγ-secreting T cells that highly express IL-2 potently inhibit the growth of intracellular M. tuberculosis in macrophages. Zhu L, Wang B, Gu J, Zhou J, Wu Y, Xu W, Yang M, Cai X, Shen H, Lu L, Wang F. Front Immunol. 2024 Nov 7;15:1469118. doi: 10.3389/fimmu.2024.1469118.
- Self-Adjuvanting Adenoviral Nanovaccine for Effective T-Cell-Mediated Immunity and Long-Lasting Memory Cell Activation against Tuberculosis. Sowndharya CK, Mehnath S, Ponbharathi A, Jeyaraj M. ACS Infect Dis. 2024 Nov 8;10(11):3939-3950. doi: 10.1021/acsinfecdis.4c00619. Epub 2024 Oct 28.
- Intravenous BCG vaccination in non-human primates induces superior serum antibody titers with enhanced avidity and opsonizing capacity compared to the intradermal route. Peralta Alvarez MP, Downward K, White A, Harris SA, Satti I, Li S, Morrison A, Sibley L, Sarfas C, Dennis M, Azema HR, Sharpe S, McShane H, Tanner R. Vaccine. 2024 Nov 9;42(26):126444. doi: 10.1016/j.vaccine.2024.126444. Epub ahead of print.
- A Cap-Optimized mRNA Encoding Multiepitope Antigen ESAT6 Induces Robust Cellular and Humoral Immune Responses Against Mycobacterium tuberculosis. Kozlova A, Pateev I, Shepelkova G, Vasileva O, Zakharova N, Yeremeev V, Ivanov R, Reshetnikov V. Vaccines (Basel). 2024 Nov 9;12(11):1267. doi: 10.3390/vaccines12111267.
- Functional impact of a deletion in Mycobacterium bovis BCG Moreau celA1 gene. Ferreira Gomes LH, Corrêa PR, Schwarz MGA, Mendonça-Lima L. Tuberculosis (Edinb). 2024. 2024 Nov 12. doi: 10.1016/j.tube.2024.102576. Epub ahead of print.
- Modeling the epidemiologic impact of age-targeted vaccination for drug-resistant tuberculosis. Zhai PY, Chen ZX, Jiang T, Feng J, Zhang B, Zang X, Zhao YL, Qin G. Drug Resist Updat. 2024 Nov 13;78:101172. doi: 10.1016/j.drup.2024.101172. Epub ahead of print.
- Mycobacterium tuberculosis Antigen Rv1471 Induces Innate Immune Memory and Adaptive Immunity against Infection. Huang X, Wu J, Xu J, Wang H, Chen Z, Fan XY, Hu Z. J Infect Dis. 2024 Nov 14:jiae572. doi: 10.1093/infdis/jiae572. Epub ahead of print.
- A mucosal vaccine formulation against tuberculosis by exploiting the adjuvant activity of S100A4-A damage-associated molecular pattern molecule. Abil OZ, Liu S, Yeh YW, Wu Y, Sen Chaudhuri A, Li NS, Deng C, Xiang Z. Vaccine. 2024 Nov 14;42(25):126151. doi: 10.1016/j.vaccine.2024.07.052. Epub 2024 Aug 1.
- A dose escalation study to evaluate the safety of an aerosol BCG infection in previously BCG-vaccinated healthy human UK adults. Fredsgaard-Jones T, Harris SA, Morrison H, Ateere A, Nassanga B, Ramon RL, Mitton C, Fletcher E, Decker J, Preston-Jones H, Jackson S, Mawer A, Satti I, Barer M, Hinks T, Bettinson H, McShane H. Front Immunol. 2024 Nov 14;15:1427371. doi: 10.3389/fimmu.2024.1427371.
- Safety and Immunogenicity of the H56:IC31 Tuberculosis Vaccine Candidate in Adults Successfully Treated for Drug-Susceptible Pulmonary Tuberculosis: A Phase 1 Randomized Trial. Tait D, Diacon A, Borges ÁH, van Brakel E, Hokey D, Rutkowski KT, Hunt DJ, Russell M, Andersen PL, Kromann I, Ruhwald M, Churchyard G, Dawson R. J Infect Dis. 2024 Nov 15;230(5):1262-1270. doi: 10.1093/infdis/jiae170.
- Analysis of a fractional order epidemiological model for tuberculosis transmission with vaccination and reinfection. Nandi TR, Saha AK, Roy S. Sci Rep. 2024 Nov 16;14(1):28290. doi: 10.1038/s41598-024-73392-x.
- In silico analysis for the development of multi-epitope vaccines against Mycobacterium tuberculosis. Yun JS, Kim AR, Kim SM, Shin E, Ha SJ, Kim D, Jeong HS. Front Immunol. 2024 Nov 18;15:1474346. doi: 10.3389/fimmu.2024.1474346.
- MTBVAC induces superior antibody titers and IgG avidity compared to BCG vaccination in non-human primates. Peralta-Álvarez MP, Downward K, White A, Redondo Azema H, Sibley L, Sarfas C, Morrison A, Dennis M, Diaz-Santana D, Harris SA, Li S, Puentes E, Aguilo N, Martin C, Sharpe S, McShane H, Tanner R. NPJ Vaccines. 2024 Nov 20;9(1):230. doi: 10.1038/s41541-024-01009-5.
- Health and Economic Impacts of Introducing Vaccae and Enhanced Drug-Resistant Tuberculosis Management Strategies in China. Zhai PY, Zang X, Jiang T, Feng J, Zhang B, Zhang L, Chen ZX, Zhao YL, Qin G. J Infect Dis. 2024 Nov 22:jiae590. doi: 10.1093/infdis/jiae590. Epub ahead of print.